The William Harvey Research Institute (WHRI) is an internationally acknowledged centre of excellence in the field of cardiovascular research and therapeutic innovation and we are proud to work closely with the Barts Heart Centre (BHC) at St Bartholomew’s Hospital, one of the largest secondary and tertiary cardiovascular centres in Europe.
An integrated NHS/University partnership to tackle cardiovascular disease
In 2015 we were awarded £10million from the Barts Charity for the creation of a world-class academic medical centre at the Barts Heart Centre, St Bartholomew's Hospital.
This investment allows us to integrate clinical care and research strategies to tackle the most pressing cardiovascular (cv) healthcare issues facing the community, with broad global relevance. These are in the areas of genomic diagnoses of rare inherited disease, innovative therapeutics for hypertension, addressing the growing burden of heart failure and establishing a state-of-the-art device innovation centre for cardiovascular disease.
The support also underpins the collaboration between Barts Health, Queen Mary University of London and UCL Partners’ aim to create the premier translational cardiovascular institute across the affiliated hospitals within the two organisations. This integrated NHS/University partnership places patient care at the centre of a strategy that connects cutting-edge cardiovascular science to Barts Health patients through the centre.
CV research programmes at the WHRI and BHC
The cardiovascular research programmes at the WHRI and BHC are closely aligned to maximise our collective expertise and strengths in areas such as pharmacological and device development that lead to innovative clinical trials for the diagnosis and treatment of heart disease whilst offering a range of professional training opportunities. Combined, our strategic approach enables the development and delivery of world-leading clinical care.
- Cardiovascular Clinical Trials Unit (CV CTU)
- CV Devices
- Genomic Medicine
- Patient Reported Outcome Measures
- Three Boroughs Project
- Pharmacotherapeutic Innovation
- Heart Failure